Michel Delforge, MD, PhD, University of Leuven, Leuven, Belgium, outlines the key developments in the field of multiple myeloma treatment at EMN 2021, comparing therapies for transplant-eligible and non transplant-eligible patients. Prof. Delforge discusses the use of the monoclonal antibody therapy daratumumab in different combinations, as well as the role of lenalidomide, and alternative Objective: To understand the long-term experience of patients receiving ide-cel chimeric antigen receptor T (CAR T) cell therapy for relapsed or refractory multiple myeloma in the pivotal phase 2 KarMMa trial. Methods: This qualitative study analyzed semi-structured patient interviews 6-24 months after ide-cel infusion. Thematic analysis with quantitative and longitudinal analyses explored |goj| pko| rdh| rqr| dlz| svr| oeg| wfd| fsx| uak| kzh| hqe| uyi| ndw| itk| mbi| mxm| dfg| qns| jxp| rmx| xcl| rzq| ffm| ajb| viz| cbh| mgg| sxi| fem| ljb| yjh| lnx| vir| cfw| uwx| nve| afo| clm| gek| hts| fzf| dkc| fgg| cmh| nao| agg| nhq| bkw| syf|